CurrentUnitedHealthcarePolicy N/A

Miplyffa (arimoclomol) prior authorization

Defines prior authorization and reauthorization requirements for Miplyffa (arimoclomol) when used to treat neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged 2 years and older; applies to UnitedHealthcare pharmacy clinical programs and affected members/providers.

Policy Summary

PayerUnitedHealthcare

PolicyMiplyffa (arimoclomol) prior authorization

Policy CodePolicy N/A

Change TypeNew prior authorizationadded contraindicated combination

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionFor initial authorization, document diagnosis of NPC and prescribe Miplyffa only in combination with miglustat (do not combine with Aqneursa).

SourceLink

POLICY UPDATE CHANGES

New prior authorization program created for Miplyffa (arimoclomol).

Criteria added that Miplyffa must not be taken in combination with Aqneursa (levacetylleucine).

4/1/2025effective date

>=2 yrsmin age

must combine with miglustattherapy requirement

12 moauth duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy — Covered when ALL of the following are met for initial authorization

Covered when ALL of the following are met for initial authorization:

Initial Authorization: Diagnosis of Niemann-Pick disease type C (NPC)

Initial Authorization: Miplyffa is used to treat neurological manifestations of NPC

Initial Authorization: Miplyffa is prescribed in combination with miglustat

Initial Authorization: Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)

Continuation Therapy / Reauthorization — Covered when ALL of the following are met for reauthorization

Covered when ALL of the following are met for reauthorization:

Reauthorization: Documentation of positive clinical response to Miplyffa (e.g., slowed disease progression from baseline assessed with NPC-specific scales)

Reauthorization: Miplyffa continues to be prescribed in combination with miglustat

Reauthorization: Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)

Use of Miplyffa (arimoclomol) in combination with Aqneursa (levacetylleucine) is excluded from coverage under this program. Requests that indicate concomitant use of these agents should be denied or will not meet the program's coverage criteria.

Initial Authorization Requirements

Initial Therapy — Initial authorization criteria

Initial authorization will be approved when ALL of the following criteria are met:

Initial authorization criteria: 1) Diagnosis of Niemann-Pick disease type C (NPC)

Based on program criteria.

Initial authorization criteria: 2) Miplyffa is used to treat neurological manifestations of NPC

Based on program criteria.

Initial authorization criteria: 3) Miplyffa is prescribed in combination with miglustat

Combination therapy required per indication.

Initial authorization criteria: 4) Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)

Concomitant use with Aqneursa is excluded from coverage.

Reauthorization and Duration

Reauthorization — Reauthorization criteria and duration

Reauthorization will be approved when ALL of the following are met; authorization length stated below:

Reauthorization criteria: 1) Documentation of positive clinical response to Miplyffa (e.g., slowed disease progression from baseline based on assessment with NPC-specific scales)

Provide clinical documentation demonstrating benefit.

Reauthorization criteria: 2) Miplyffa continues to be prescribed in combination with miglustat

Combination therapy must be maintained.

Reauthorization criteria: 3) Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)

Concomitant use with Aqneursa remains excluded.

Reauthorization duration: Authorization will be issued for 12 months when reauthorization criteria are met.12 months

State mandates and member benefit plans may also impact coverage.

Provider Actions, Documentation, and Operational Rules

Prior Authorization

Initial Authorization Requirements

Prior authorization required. Provider must submit diagnosis, indication, and concomitant therapy details as part of the initial authorization request.

Diagnosis: Niemann-Pick disease type C (NPC)
Indication: Neurological manifestations of NPC
Concomitant therapy: Miplyffa must be prescribed in combination with miglustat
Exclusion: Patient must not be receiving Miplyffa concurrently with Aqneursa (levacetylleucine)

Documentation Required

Reauthorization Clinical Response Documentation

Reauthorization requires documentation demonstrating a positive clinical response to Miplyffa for continued coverage.

Documentation: Evidence of positive clinical response (e.g., slowed disease progression from baseline assessed with NPC-specific scales)
Concomitant therapy must be continued: Miplyffa must continue to be prescribed in combination with miglustat
Exclusion: Patient must not be receiving Miplyffa concurrently with Aqneursa (levacetylleucine)

Billing Rule

Automated Approval and Supply Limits

Automated approval and supply limits may apply; prior claim or medication history, diagnosis codes, and claim logic can be used to approve initial authorizations and reauthorizations.

Automated approval: UnitedHealthcare may approve initial or reauthorization requests based solely on previous claim/medication history, ICD-10 diagnosis codes, and/or claim logic as permitted by program rules
Re-approval: Automated re-approval processes may be used where program/therapeutic-class specific rules allow
Supply limits: Quantity or supply limits may be applied per plan or program

Denial Risk

Incompatible / Concomitant Therapy Denial Conditions

Denial risk if incompatible or missing required concomitant therapy.

Denial: Requests will be denied if Miplyffa is prescribed concurrently with Aqneursa (levacetylleucine)
Denial: Requests will be denied if Miplyffa is not prescribed in combination with required agent(s) (miglustat)

Key Definitions

miglustat

DefinitionMiglustat — the required concomitant therapy with Miplyffa per the FDA‑labeled indication (Miplyffa is indicated for use in combination with miglustat for treatment of neurological manifestations of Niemann‑Pick disease type C).

Role in Coverage CriteriaInitial and reauthorization criteria both require that Miplyffa be prescribed in combination with miglustat.

Patient PopulationApplicable for adult and pediatric patients 2 years of age and older when treating neurological manifestations of NPC.

Aqneursa (levacetylleucine)

DefinitionAqneursa (levacetylleucine) — medication explicitly stated as not to be used in combination with Miplyffa for coverage under this program.

Coverage ExclusionRequests will be denied if Miplyffa is prescribed concurrently with Aqneursa (levacetylleucine).

Authorization Criteria ImpactBoth initial authorization and reauthorization require that the patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine).

Background

Miplyffa (arimoclomol) is indicated for the treatment of neurological manifestations of Niemann‑Pick disease type C (NPC) when used in combination with miglustat in patients aged 2 years and older. Per the program, initiation and continuation of Miplyffa require that it be prescribed together with miglustat and that it not be given concurrently with Aqneursa (levacetylleucine). Reauthorization requires documented positive clinical response and, when criteria are met, authorization is issued for 12 months.

Revision History and Policy Changes

2024-11P&T approval

Program was reviewed and approved by the Pharmacy & Therapeutics (P&T) committee (P&T approval recorded 11/2024).

2025-01Program creation

New prior authorization program for Miplyffa (arimoclomol) was created (documented as change in 1/2025).

2025-04-01Effective dateLatest

The Miplyffa prior authorization program became effective on April 1, 2025.

Policy Summary

PayerUnitedHealthcare

PolicyMiplyffa (arimoclomol) prior authorization

Policy CodePolicy N/A

Change TypeNew prior authorizationadded contraindicated combination

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionFor initial authorization, document diagnosis of NPC and prescribe Miplyffa only in combination with miglustat (do not combine with Aqneursa).

SourceLink

On This Page

OpenPayer

Miplyffa (arimoclomol) prior authorization

Coverage Criteria for Miplyffa (arimoclomol)

Initial Authorization Requirements

Reauthorization and Duration

Provider Actions, Documentation, and Operational Rules

Key Definitions

Background

Revision History and Policy Changes